Intellia Therapeutics (NTLA) Tops Q4 EPS by 7c
Tweet
Share
E-mail
Get Alerts NTLA Hot Sheet
Join SI Premium – FREE
Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($1.27), $0.07 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $12.87 million versus the consensus estimate of $9.28 million.
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Upgrades 1&1 AG (1U1:GR) to Overweight
- Goldman Sachs Upgrades Primoris Services Corporation (PRIM) to Neutral
- Lonza Group (LONN:SW) (LZAGY) PT Raised to CHF720 at RBC Capital
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
